184 related articles for article (PubMed ID: 31151416)
1. Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma.
Schiffmann LM; Göbel H; Löser H; Schorn F; Werthenbach JP; Fuchs HF; Plum PS; Bludau M; Zander T; Schröder W; Bruns CJ; Kashkar H; Quaas A; Gebauer F
BMC Cancer; 2019 May; 19(1):531. PubMed ID: 31151416
[TBL] [Abstract][Full Text] [Related]
2. The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation.
Humphries MP; Craig SG; Kacprzyk R; Fisher NC; Bingham V; McQuaid S; Murray GI; McManus D; Turkington RC; James J; Salto-Tellez M
BMC Cancer; 2020 Jun; 20(1):500. PubMed ID: 32487090
[TBL] [Abstract][Full Text] [Related]
3. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
[TBL] [Abstract][Full Text] [Related]
4. X-linked inhibitor of apoptosis protein is a prognostic marker for a favorable outcome in three identified subsets in resectable adenocarcinoma of the pancreas.
Knipper K; Lyu SI; Goebel H; Damanakis AI; Zhao Y; Bruns CJ; Schmidt T; Kashkar H; Quaas A; Schiffmann LM; Popp FC;
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5531-5538. PubMed ID: 36472768
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant treatment response in negative nodes is an important prognosticator after esophagectomy.
Nieman DR; Peyre CG; Watson TJ; Cao W; Lunt MD; Lada MJ; Han MS; Jones CE; Peters JH
Ann Thorac Surg; 2015 Jan; 99(1):277-83. PubMed ID: 25442991
[TBL] [Abstract][Full Text] [Related]
7. Molecular markers predicting lymph node metastasis in early esophageal cancer.
Plum PS; Warnecke-Eberz U; Dhaouadi O; Alakus H; Drebber U; Metzger R; Prenzel KL; Hölscher AH; Bollschweiler E
Histol Histopathol; 2015 Oct; 30(10):1193-202. PubMed ID: 25869644
[TBL] [Abstract][Full Text] [Related]
8. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
[TBL] [Abstract][Full Text] [Related]
9. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
[TBL] [Abstract][Full Text] [Related]
10. The X-linked inhibitor of apoptosis protein is an independent prognostic marker for rectal adenocarcinoma after preoperative chemoradiotherapy.
Chen YT; Tsao SC; Tsai HP; Wang JY; Chai CY
Virchows Arch; 2016 May; 468(5):559-67. PubMed ID: 26915033
[TBL] [Abstract][Full Text] [Related]
11. P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy.
van Olphen SH; Biermann K; Shapiro J; Wijnhoven BP; Toxopeus EL; van der Gaast A; Stoop HA; van Lanschot JJ; Spaander MC; Bruno MJ; Looijenga LH
Ann Surg; 2017 Feb; 265(2):347-355. PubMed ID: 28059963
[TBL] [Abstract][Full Text] [Related]
12. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
[TBL] [Abstract][Full Text] [Related]
13. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
[TBL] [Abstract][Full Text] [Related]
14. Outcome with Primary En-bloc Esophagectomy for Submucosal Esophageal Adenocarcinoma.
Schwameis K; Green KM; Worrell SG; Samaan J; Cooper S; Tatishchev S; Oh DS; Hagen JA; DeMeester SR
Ann Surg Oncol; 2017 Dec; 24(13):3921-3925. PubMed ID: 28975518
[TBL] [Abstract][Full Text] [Related]
15. Impact of response evaluation for resectable esophageal adenocarcinoma - a retrospective cohort study.
Bachmann R; Bachmann J; Hungbauer A; Schmehl J; Sitzmann G; Königsrainer A; Ladurner R
Int J Surg; 2014 Oct; 12(10):1025-30. PubMed ID: 25192805
[TBL] [Abstract][Full Text] [Related]
16. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation.
Raouf AA; Evoy DA; Carton E; Mulligan E; Griffin MM; Reynolds JV
Dis Esophagus; 2003; 16(1):17-23. PubMed ID: 12581249
[TBL] [Abstract][Full Text] [Related]
17. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
18. Metabolic tumor constitution is superior to tumor regression grading for evaluating response to neoadjuvant therapy of esophageal adenocarcinoma patients.
Buck A; Prade VM; Kunzke T; Feuchtinger A; Kröll D; Feith M; Dislich B; Balluff B; Langer R; Walch A
J Pathol; 2022 Feb; 256(2):202-213. PubMed ID: 34719782
[TBL] [Abstract][Full Text] [Related]
19. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
